Basilea Pharmaceutica AG (0QNA.L)
CHF 41.65
(-2.93%)
CHF 41.65
(-2.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 183.29 Million CHF | -24.12% |
| 2022 | 241.56 Million CHF | -21.03% |
| 2021 | 305.87 Million CHF | -7.82% |
| 2020 | 331.84 Million CHF | 5.54% |
| 2019 | 314.42 Million CHF | -9.76% |
| 2018 | 348.43 Million CHF | -11.25% |
| 2017 | 392.6 Million CHF | 8.23% |
| 2016 | 362.75 Million CHF | -5.5% |
| 2015 | 383.87 Million CHF | 92.47% |
| 2014 | 199.44 Million CHF | -12.86% |
| 2013 | 228.88 Million CHF | -15.18% |
| 2012 | 269.84 Million CHF | 221.93% |
| 2011 | 83.82 Million CHF | -21.15% |
| 2010 | 106.3 Million CHF | -2.37% |
| 2009 | 108.87 Million CHF | -15.19% |
| 2008 | 128.38 Million CHF | 1.61% |
| 2007 | 126.34 Million CHF | 39.18% |
| 2006 | 90.77 Million CHF | 3.52% |
| 2005 | 87.69 Million CHF | 314.02% |
| 2004 | 21.18 Million CHF | 26.6% |
| 2003 | 16.73 Million CHF | -33.43% |
| 2002 | 25.13 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 171.87 Million CHF | 0.0% |
| 2023 FY | 183.29 Million CHF | -24.12% |
| 2023 Q2 | 215.04 Million CHF | 0.0% |
| 2023 Q4 | 183.29 Million CHF | 0.0% |
| 2022 Q4 | 241.56 Million CHF | 0.0% |
| 2022 FY | 241.56 Million CHF | -21.03% |
| 2022 Q2 | 303.23 Million CHF | 0.0% |
| 2021 FY | 305.87 Million CHF | -7.82% |
| 2021 Q2 | 305.92 Million CHF | 0.0% |
| 2021 Q4 | 305.87 Million CHF | 0.0% |
| 2020 FY | 331.84 Million CHF | 5.54% |
| 2020 Q4 | 331.84 Million CHF | 0.0% |
| 2020 Q2 | 276.63 Million CHF | 0.0% |
| 2019 FY | 314.42 Million CHF | -9.76% |
| 2019 Q2 | 315.63 Million CHF | 0.0% |
| 2019 Q4 | 314.42 Million CHF | 0.0% |
| 2018 Q2 | 363.33 Million CHF | 0.0% |
| 2018 FY | 348.43 Million CHF | -11.25% |
| 2018 Q4 | 348.43 Million CHF | 0.0% |
| 2017 Q4 | 392.6 Million CHF | 0.0% |
| 2017 Q2 | 344.54 Million CHF | 0.0% |
| 2017 FY | 392.6 Million CHF | 8.23% |
| 2016 Q4 | 362.75 Million CHF | 0.0% |
| 2016 Q2 | 354.62 Million CHF | 0.0% |
| 2016 FY | 362.75 Million CHF | -5.5% |
| 2015 FY | 383.87 Million CHF | 92.47% |
| 2015 Q4 | 383.87 Million CHF | 0.0% |
| 2015 Q2 | 204.82 Million CHF | 0.0% |
| 2014 Q2 | 202.21 Million CHF | 0.0% |
| 2014 FY | 199.44 Million CHF | -12.86% |
| 2014 Q4 | 199.44 Million CHF | 0.0% |
| 2013 Q2 | 247.18 Million CHF | 0.0% |
| 2013 FY | 228.88 Million CHF | -15.18% |
| 2013 Q4 | 228.88 Million CHF | 0.0% |
| 2012 Q4 | 269.84 Million CHF | 0.0% |
| 2012 FY | 269.84 Million CHF | 221.93% |
| 2012 Q2 | 69.13 Million CHF | 0.0% |
| 2011 Q2 | 86.07 Million CHF | 0.0% |
| 2011 FY | 83.82 Million CHF | -21.15% |
| 2011 Q4 | 83.82 Million CHF | 0.0% |
| 2010 Q2 | 150.65 Million CHF | 0.0% |
| 2010 FY | 106.3 Million CHF | -2.37% |
| 2010 Q4 | 106.3 Million CHF | 0.0% |
| 2009 Q4 | 108.87 Million CHF | 0.0% |
| 2009 FY | 108.87 Million CHF | -15.19% |
| 2008 FY | 128.38 Million CHF | 1.61% |
| 2007 FY | 126.34 Million CHF | 39.18% |
| 2006 FY | 90.77 Million CHF | 3.52% |
| 2005 FY | 87.69 Million CHF | 314.02% |
| 2004 FY | 21.18 Million CHF | 26.6% |
| 2003 FY | 16.73 Million CHF | -33.43% |
| 2002 FY | 25.13 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 24.16 Million CHF | -658.596% |
| Tecan Group AG | 725.05 Million CHF | 74.72% |
| Santhera Pharmaceuticals Holding AG | 49.68 Million CHF | -268.901% |
| Bachem Holding AG | 362.35 Million CHF | 49.417% |
| Siegfried Holding AG | 1.02 Billion CHF | 82.089% |
| Molecular Partners AG | 21.92 Million CHF | -736.072% |